Contract number
075-15-2019-1925
075-15-2022-1103
Time span of the project
2019-2023
As of 15.02.2021
26
Number of staff members
36
scientific publications
2
Objects of intellectual property
Name of the project: Development of targeted molecules based on framework proteins for diagnostics and treatment of malignant tumors: theranostic approach
Strategy for Scientific and Technological Development Priority Level: в
Project objective: сreation of a laboratory for development of targeted molecules based on framework proteins, specific to molecular targets expressed on tumor cells. The Laboratory will work as a competence center in the domain of development of radiopharmaceuticals for diagnostics and treatment of oncological diseases using methods of nuclear medicine
Oroujeni, M., Rinne, S.S., Vorobyeva, A., Loftenius, A., Feldwisch, J., Jonasson, P., Chernov, V., Orlova, A., Frejd, F.Y., Tolmachev, V.
Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake //International Journal of Molecular Sciences. – 2021. – Vol. 22. – No. 2770. DOI:10.3390/ijms22052770 https://www.mdpi.com/1422-0067/22/5/2770
Garousi, J., von Witting, E., Borin, J., Vorobyeva, A., Altai, M., Vorontsova, O., Konijnenberg, M.W., Oroujeni, M., Orlova, A., Tolmachev, V. Hober, S.
Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle //Biomaterials. – 2021. – Vol. 266. – P. 120381.
Tolmachev, V., Orlova, A., & Sörensen, J.
The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer //Seminars in Cancer Biology. – Academic Press, 2021. DOI: 10.1016/j.semcancer.2020.10.005 https://www.sciencedirect.com/science/article/pii/S1044579X20302108
Bragina O, von Witting E, Garousi J, Zelchan R, Sandström M, Orlova A, Medvedeva A, Doroshenko A, Vorobyeva A, Lindbo S, Borin J, Tarabanovskaya N, Sörensen J, Hober S, Chernov V, Tolmachev V.
Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer. J Nucl Med. 2021 Apr;62(4):493-499. doi: 10.2967/jnumed.120.248799.
Deyev, S.M., Vorobyeva, A., Schulga, A., Abouzayed, A., Gunther, T., Garousi, J., Konovalova, E., Ding, H., Graslund, T., Orlova, A., Tolmachev, V.
Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1 //International Journal of Biological Macromolecules. – 2020. – Vol. 145. – P. 216-225. DOI: 10.1016/j.ijbiomac.2019.12.147
Tolmachev, V., Orlova, A.
Affibody molecules as targeting vectors for PET imaging //Cancers. – 2020. – Vol. 12. – No. 3. – P. 651. DOI: 10.3390/cancers12030651 https://www.mdpi.com/2072-6694/12/3/651
Vorobyeva A, Konovalova E, Xu T, Schulga A, Altai M, Garousi J, Rinne SS, Orlova A, Tolmachev V, Deyev S.
Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1 // International Journal of Molecular Sciences. – 2020. – Т. 21. – №. 9. – С. 3310, doi: 10.3390/ijms21093310
Tano, H., Oroujeni, M., Vorobyeva, A., Westerlund, K., Liu, Y., Xu, T., Vasconcelos, D., Orlova, A., Karlström, A.E., Tolmachev, V.
Comparative Evaluation of Novel 177Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting //Cancers. – 2021. – Vol. 13. – No. 3. – P. 500. DOI: 10.3390/cancers13030500 https://www.mdpi.com/2072-6694/13/3/500
Hosting organization
|
Field of studies
|
City
|
Invited researcher
|
Time span of the project
|
---|---|---|---|---|
Laboratory for Experimental Oncology
N. I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation - (Pirogov Medical University) |
Clinical medicine |
Moscow |
Conrad Marcus
Шохина Арина Геннадиевна
Russia |
2019-2021 |
Laboratory for System Medicine for Healthy Ageing
Lobachevsky State University of Nizhny Novgorod - (UNN) |
Clinical medicine |
Nizhniy Novgorod |
Franceschi Claudio
Italy |
2018-2022 |